Tess from Spain

Registered at the short selling broker Capital, 2 minutes ago.

» Try Capital you too
71.2% of retail investor accounts lose money when trading CFDs with Capital.
Don't show again

Sanofi (SNY) shares information

Sanofi – ADR

24h Change

1.14 %


Live rate: Market closed

Stock data per Monday 10 May, 2021

0.59 (+ 1.14%)
US Market is closed

Live Stock price in graph for Sanofi – ADR (SNY)

  • Latest Volume

    1,151,741 (-46.74 %)

  • Volume prev. day


  • Avg. daily volume


  • Market cap


  • P/E ratio


  • Today high


  • Today low


  • 52 week high

    53 USD

  • 52 week low

    43.13 USD

  • YTD Change

    + 11.81 %

Quick links


Latest news about Sanofi – ADR

Below you can find the most recent news posts about Sanofi – ADR, primarily from US and UK based news sources.

Sanofi's valuations attractive: Should you invest?

Monday, 3 May 2021, 03:00:00
Chronic therapeutic treatments contribute around 63% of Sanofi India’s domestic sales and the same is now under several restrictions due to the Covid-19 related disturbances. The company’s growth opportunities should improve once the situation stabilises and patients start coming back to the hospitals for treatment of other diseases. Despite short-term challenges, Sanofi continues to do well and was able to beat the street expectations with its results for the first quarter of 2021. While its q-o-q revenue remained stable, its y-o-y revenue declined by 8%. However, this decline was due to the divestment of its Ankleshwar plant and discontinuation of a few products to Zentiva. Its adjusted revenue growth is placed at 9% y-o-y. Its qo-q gross margin which declined mostly because of the increased contribution from low margin imports was offset by operational cost savings. Its q-o-q ebitda and net profit grew by 13% and 19% respectively. 82342643 !function(){“use strict”;window.addEventListener(“message”,(function(a){if(void 0!==a.data[“datawrapper-height”])for(var e in a.data[“datawrapper-height”]){var t=document.getElementById(“datawrapper-chart-“+e)||document.querySelector(“iframe[src*='”+e+”‘]”);t&&(t.style.height=a.data[“datawrapper-height”][e]+”px”)}}))}(); Despite being a mid-cap pharma company, analysts continue to impose their faith in Sanofi India due to its long term growth outlook.
— Economic Times India

Sanofi Shares Rise On Q1 Sales Boosted By Dupixent Franchise; Plans To Restart Haemophilia Study With Fitusiran

Wednesday, 28 April 2021, 19:27:23
Sanofi SA (NASDAQ: SNY ) stock climbed after its Q1 earnings beat earnings expectations and stuck to its full-year guidance, as well as reported progress on its delayed COVID-19 vaccine efforts. Earnings: Overall sales increased by 2.4%, attributed mainly to Dupixent’s success, with vaccines also contributing with a 5.3% rise in sales to €915 million. The Regeneron Pharmaceuticals Inc (NASDAQ: REGN )-partnered drug pulled in more than €1 billion worldwide for a year-over-year increase of 45.6% at the common exchange rate. Dupixent also scored a spot on China’s coveted National Reimbursement Drug List in March, marking the official launch of Dupixent in one of the world’s largest markets. Two of Sanofi’s … Full story available on Benzinga.com
— Benzinga

Eczema treatment and vaccines lift Sanofi first quarter results

Wednesday, 28 April 2021, 09:15:49
— Investing.com

Sanofi Steps In For Fill-Finish 200M Doses Of Moderna's COVID-19 Vaccine

Monday, 26 April 2021, 15:18:32
As the demand for mRNA-based COVID-19 vaccines persists, Sanofi SA (NASDAQ: SNY ) has entered an agreement with Moderna Inc (NASDAQ: MRNA ) to manufacture its COVID-19 vaccine in the U.S. The agreement marks the third different company Sanofi has paired with to manufacture a COVID-19 vaccine since their effort to develop a shot faced significant setbacks. Sanofi will perform fill-and-finish at its Ridgefield facility in New Jersey to complete up to 200 million doses of the vaccine beginning in September. The financial details of the arrangement were not … Full story available on Benzinga.com
— Benzinga

Sanofi-AstraZeneca's Nirsevimab Hits Primary Endpoint Goal In Late-Stage RSV Disease In Infants

Monday, 26 April 2021, 12:16:21
Sanofi SA (NASDAQ: SNY ) and AstraZeneca Plc’s (NASDAQ: AZN ) monoclonal antibody (mAb) nirsevimab has reached its primary endpoint in a Phase 3 trial, demonstrating protection against respiratory syncytial virus disease (RSV) in healthy infants. The data comes earlier than anticipated; regulatory submissions for all-infant indications are expected to begin in 2022. Nirsevimab, an investigational extended half-life … Full story available on Benzinga.com
— Benzinga

Trading broker recommendation

We recommend that you check out Capital.com as they have a very good selection of stocks available for both going short and long.

Rating: 9.57/10
Minimum deposit: €250 by bank
Description: Capital.com offer a large number of stocks for trading. Register an account today and check if they have SNY available or trade one of the many other CFD stocks they have.
Risk warning: 71.2% of retail investor accounts lose money when trading CFDs with Capital.